GlaxoSmithKline Pharmaceuticals

3,260.00
-25.00
(-0.76%)
Market Cap
55,226.37 Cr
EPS
54.76
PE Ratio
63.61
Dividend Yield
1.65 %
Industry
Healthcare
52 Week High
3,515.70
52 Week Low
1,921.00
PB Ratio
28.49
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell+25.00 %
+25.00 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,665.20
#1 3,99,537.26
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,919.50
1,83,690.98
83.40
9,360.00
0.89
2,117
23.05
68.54
1,491.90
1,20,501.93
23.71
28,409.50
7.12
5,291
30.28
54.26
3,322.00
1,12,431.58
59.20
11,539.40
11.59
1,911
10.91
62.08
1,281.30
1,06,933.59
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,417.00
99,756.54
50.14
12,207.40
19.57
1,925
-10.91
59.65
975.30
98,138.00
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,917.60
87,575.92
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,035.00
72,322.00
51.77
6,409.15
10.80
1,417
27.83
64.97
1,143.50
66,414.67
19.91
31,378.10
17.55
3,366
-0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
4,108
Fixed Assets
123
210
258
325
432
758
387
331
330
321
284
Current Assets
2,587
2,174
1,674
2,186
2,010
1,775
2,203
3,708
2,494
2,798
3,410
Capital Work in Progress
115
268
606
923
1,003
120
13
31
20
14
14
Investments
0
0
0
0
0
0
0
366
518
813
1,118
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
2,692
Total Liabilities
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
4,108
Current Liabilities
1,107
579
720
1,600
1,454
1,024
1,355
1,698
1,326
1,525
1,905
Non Current Liabilities
280
292
277
290
317
291
282
272
259
254
252
Total Equity
1,829
2,183
2,007
2,057
2,140
1,821
1,478
2,663
1,741
1,778
1,951
Reserve & Surplus
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
1,782
Share Capital
85
85
85
85
169
169
169
169
169
169
169

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
21
-0
24
62
-102
6
300
-119
-251
29
475
Investing Activities
180
499
301
-104
-153
-57
418
-406
808
9
-46
Operating Activities
338
139
234
473
410
491
578
811
484
582
1,290
Financing Activities
-497
-638
-511
-307
-358
-428
-696
-524
-1,543
-562
-769

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.48 %
4.02 %
4.36 %
4.50 %
4.52 %
DIIs
5.31 %
5.51 %
5.50 %
5.61 %
5.61 %
4.08 %
10.45 %
10.28 %
10.30 %
10.23 %
10.01 %
8.53 %
7.90 %
7.50 %
7.34 %
7.30 %
7.79 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
11.02 %
10.86 %
10.83 %
10.67 %
10.41 %
10.41 %
10.40 %
10.56 %
10.54 %
10.57 %
10.62 %
11.08 %
11.27 %
11.15 %
10.97 %
10.96 %
10.60 %
Others
8.67 %
8.62 %
8.67 %
8.73 %
8.98 %
10.51 %
4.15 %
4.16 %
4.16 %
4.20 %
4.37 %
5.38 %
2.35 %
2.33 %
2.33 %
2.23 %
2.09 %
No of Share Holders
1,19,951
1,20,476
1,21,445
1,23,480
1,10,141
1,12,964
1,16,651
1,20,127
1,20,415
1,19,032
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 30 35 20 40 30 90 32 32 54
Dividend Yield (%) 0.00 2.87 2.7 1.59 2.78 1.8 7.05 1.64 1.11 1.64

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
01 Aug 2025 3,301.90 3,281.65
27 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Jun 2025 2,788.70 3,457.70
30 May 2025 DIVIDEND Dividend
₹ 42.00 /share
30 May 2025 2,788.70 3,295.00
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 2,906.80 2,788.70
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 2,042.50 2,017.75
07 Nov 2024 DIVIDEND Dividend
₹ 12.00 /share
07 Nov 2024 2,629.75 2,611.50
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 2,618.05 2,629.75
28 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2024 2,287.00 2,652.30
31 May 2024 DIVIDEND Dividend
₹ 32.00 /share
31 May 2024 2,287.00 2,619.30
30 Jun 2023 DIVIDEND Dividend
₹ 32.00 /share
30 Jun 2023 1,291.65 1,425.10
26 Jul 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2022 1,514.10 1,461.45
08 Jul 2022 DIVIDEND Dividend
₹ 60.00 /share
07 Jul 2022 1,514.10 1,494.55
08 Jul 2022 DIVIDEND Dividend
₹ 30.00 /share
07 Jul 2022 1,514.10 1,494.55
20 Jul 2021 DIVIDEND Dividend
₹ 30.00 /share
19 Jul 2021 1,516.45 1,604.40
13 Sept 2018 BONUS Bonus
1:1
11 Sept 2018 1,736.18 1,724.70

Announcements

Board Meeting Intimation for Board Meeting Intimation 3 days ago
Outcome Of AGM10 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers Report10 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM10 days ago
Disclosure Under Regulation 3010 days ago
Closure of Trading WindowJun 26, 2025
Analyst MeetJun 20, 2025
Disclosure Under Regulation 30Jun 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Letter To Shareholders For Annual Report LinkJun 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
100Th Annual General Meeting On 27Th June 2025Jun 03, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Reg. 34 (1) Annual Report.Jun 03, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Disclosure Under Regulation 30May 16, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
Appointment Of Parikh & Associates As Secretarial Auditor Of The Company May 13, 2025
100Th Annual General Meeting On 27Th June 2025May 13, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
Record Date For Final Dividend 30Th May 2025May 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Corporate Action-Board approves DividendMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Outcome Of MeetingMay 13, 2025
Board Meeting Outcome for Outcome Of MeetingMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 02, 2025
Disclosure Under Regulation 30Apr 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 29, 2025
Increase In VolumesApr 25, 2025
Increase In VolumesApr 25, 2025
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) For The Quarter / Year Ended 31St March 2025Apr 17, 2025
Disclosure Under Regulation 30Apr 11, 2025
Disclosure Under Regulation 30Apr 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 31, 2025
Postal Ballot NoticeMar 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 26, 2025
Board Meeting Outcome for Change In DirectorateMar 26, 2025

Technical Indicators

RSI(14)
Neutral
52.17
ATR(14)
Less Volatile
107.12
STOCH(9,6)
Neutral
43.17
STOCH RSI(14)
Neutral
27.82
MACD(12,26)
Bearish
-14.83
ADX(14)
Strong Trend
35.75
UO(9)
Bearish
37.85
ROC(12)
Uptrend And Accelerating
2.68
WillR(14)
Neutral
-62.12

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Mid Cap Direct Plan-Growth
0.00%
-1696276
-2.50%
-2.34%
Kotak Large & Midcap Fund Direct-Growth
0.00%
-1100000
-1.34%
-1.27%
Nippon India Pharma Fund Direct-Growth
0.00%
-943731
-3.73%
-3.63%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.00%
-763852
-1.64%
-1.74%
Nippon India Growth Mid Cap Fund Direct- Growth
0.00%
-559000
-0.50%
-0.48%
SBI Dividend Yield Fund Direct - Growth
0.00%
-450000
-1.62%
-1.49%
Kotak Flexicap Fund Direct-Growth
0.00%
-399331
-0.25%
-0.23%
Aditya Birla Sun Life MNC Fund Direct-Growth
0.00%
-317523
-2.85%
-3.35%
Bandhan ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-301920
-1.43%
-1.44%
Mahindra Manulife Small Cap Fund Direct - Growth
0.00%
-174000
-1.49%
-1.16%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
-146831
-1.00%
-0.59%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.00%
-144565
-0.75%
-0.71%
Edelweiss Business Cycle Fund Direct-Growth
0.00%
-141645
-2.54%
0.00%
Baroda BNP Paribas Midcap Fund Direct-Growth
0.00%
-136783
-2.11%
-1.99%
Bandhan Multi Cap Fund Direct-Growth
0.00%
-111044
-1.40%
-1.54%
SBI Quant Fund Direct-Growth
0.00%
-107042
-0.94%
-0.45%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
0.00%
-101872
-1.69%
-1.61%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-100000
-1.36%
-1.29%
Helios Flexi Cap Fund Direct - Growth
0.00%
-84390
-0.87%
-0.84%
Bajaj Finserv Multi Asset Allocation Fund Direct-Growth
0.00%
-78614
-2.20%
-1.75%
JM Midcap Fund Direct - Growth
0.00%
-76716
-1.81%
-1.73%
Axis Quant Fund Direct-Growth
0.00%
-71213
-2.43%
-2.19%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.00%
-69775
-2.83%
-2.53%
360 ONE Quant Fund Direct - Growth
0.00%
-68573
-3.19%
-1.69%
Baroda BNP Paribas Dividend Yield Fund Direct-Growth
0.00%
-65000
-2.18%
-1.83%

About GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Chairperson NameRenu S Karnad